Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro January 11, 2026
Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Gen Bispecific ADCs January 11, 2026
STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications January 11, 2026
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies January 11, 2026
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development January 11, 2026
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration January 11, 2026
Insilico Medicine Announces US$888M Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology January 4, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates January 4, 2026
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly January 4, 2026
BioAtla and GATC Health Announce a $40M SPV Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ OPSCC January 4, 2026
AbbVie secured global rights outside China to ZG006 (alveltamig) developed by Suzhou Zelgen Biopharmaceuticals January 4, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates December 30, 2025
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly December 30, 2025
Oncodesign Precision Medicine and Navigo Proteins announce the end of their collaboration in the development of radiotheranostics December 30, 2025
Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 December 30, 2025
Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial of bexmarilimab + zimberelimab December 30, 2025
Athira Pharma Announces Exclusive License to Lasofoxifene Ph 3 Development Program for Metastatic Breast Cancer Candidate and Financing for up to $236M December 30, 2025
LIXTE Biotechnology, The University of Texas MD Anderson Cancer Center, and GSK expand collaboration on LB-100 to treat ovarian clear cell cancer December 30, 2025
GMP Manufacturing of AKTX-101 ADC Program Initiated to Support Ph 1 First-in-Human Clinical Trial December 30, 2025
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic December 22, 2025
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need December 22, 2025
